Skip to main content
. 2021 Aug 7;13(1):1955811. doi: 10.1080/19420862.2021.1955811

Figure 9.

Figure 9.

Relative abundance of all HCP identified in approved therapeutic proteins (N = 28) and proteins (N = 12) produced in house using a first-in-human (FIH) platform process and commercially enabling process. Points are colored by relative abundance. Mean is indicated by red line and annotated. Drug 1 was not included in this analysis